Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-3,851
Closed -$1.39M – 568
2026
Q2
$1.39M Sell
3,851
-3,259
-46% -$1.12M 0.24% 93
2026
Q1
$2.5M Buy
7,110
+2,020
+40% +$720K 0.62% 28
2025
Q4
$1.67M Sell
5,090
-1,753
-26% -$556K 0.36% 52
2025
Q3
$1.93M Buy
+6,843
New +$1.98M 0.37% 50
2025
Q2
– Sell
-5,072
Closed -$1.58M – 512
2025
Q1
$1.58M Buy
5,072
+3,496
+222% +$1.03M 0.31% 69
2024
Q4
$411K Buy
+1,576
New +$468K 0.09% 250

Other funds holding AMGN

111 Capital's AMGN Position: Q3 2026 in Review

111 Capital sold out of Amgen (AMGN) in Q3 2026, closing a stake of 3,851 shares — an estimated $1.39M sold.

111 Capital first reported a position in AMGN in Q4 2024 and held it in 6 quarters. The position peaked at $2.5M in Q1 2026. 3,271 funds tracked by Wall St. Rank hold AMGN as of Q3 2026.

  • 111 Capital reported no remaining Amgen position as of Q3 2026 after selling out during the quarter.
  • 111 Capital sold 3,851 Amgen shares in Q3 2026, an estimated $1.39M.
  • 111 Capital first reported a position in Amgen in Q4 2024 and held it in 6 quarters.
  • 111 Capital's Amgen position peaked at $2.5M in Q1 2026.
  • 3,271 funds tracked by Wall St. Rank held Amgen as of Q3 2026.

Based on 111 Capital's 13F filing for Q3 2026, filed 3 Nov 2026.